Insider trade

Officer sold ~$157K of CYTK shares in the open market

Traded Mar 9, 2026 · Filed Mar 10, 2026

Why it stands out

Cytokinetics's Chief Commercial Officer sold $157K of Cytokinetics shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$156,779

Shares × reported transaction price

Timing vs results

13 days after results of Feb 24, 2026, 57 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references tax withholding

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−2.3%	−2.2%	−0.1%
30 days	+2.2%	+0.5%	+1.7%
90 days	+7.6%	+9.0%	−1.4%
180 days	+18.4%	+13.3%	+5.2%

Past results only. Not a forecast.

Sell to cover transaction to satisfy company tax withholding obligations upon vesting of RSUs.

6mo ago

Derivative exercise or conversion — not an open-market buy.

Automatic sale6mo ago

6mo ago

Derivative exercise or conversion — not an open-market buy.